See more : UMC Electronics Co., Ltd. (6615.T) Income Statement Analysis – Financial Results
Complete financial analysis of Intercept Pharmaceuticals, Inc. (ICPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intercept Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fengxing Co., Ltd. (002760.SZ) Income Statement Analysis – Financial Results
- Friedman Industries, Incorporated (FRD) Income Statement Analysis – Financial Results
- Diversified Oil & Gas Holdings, Ltd. (DVFI) Income Statement Analysis – Financial Results
- Apogee Enterprises, Inc. (APOG) Income Statement Analysis – Financial Results
- Australian Clinical Labs Limited (ACL.AX) Income Statement Analysis – Financial Results
Intercept Pharmaceuticals, Inc. (ICPT)
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 285.71M | 363.47M | 312.69M | 252.00M | 179.80M | 130.96M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
| Cost of Revenue | 984.00K | 3.10M | 5.32M | 4.21M | 2.52M | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 284.73M | 360.37M | 307.37M | 247.79M | 177.29M | 129.59M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
| Gross Profit Ratio | 99.66% | 99.15% | 98.30% | 98.33% | 98.60% | 98.95% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 176.64M | 185.27M | 191.49M | 242.80M | 207.30M | 191.50M | 153.89M | 128.19M | 80.31M | 27.94M | 16.18M | 11.43M | 12.71M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 255.47M | 0.00 | 0.00 | 103.75M | 34.60M | 13.13M | 4.85M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -161.00 | 331.87K | 0.00 | 0.00 |
| SG&A | 176.30M | 230.86M | 332.49M | 317.42M | 255.47M | 273.70M | 273.60M | 103.75M | 34.60M | 13.13M | 5.18M | 4.21M | 3.64M |
| Other Expenses | 6.52M | 2.16M | 4.41M | 8.89M | 6.77M | 4.52M | 3.90M | 2.73M | 776.00K | 100.38K | -104.00K | 0.00 | 104.55K |
| Operating Expenses | 352.94M | 416.13M | 523.98M | 560.22M | 462.78M | 465.20M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
| Cost & Expenses | 353.93M | 419.23M | 529.30M | 564.43M | 465.29M | 466.57M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
| Interest Income | 15.51M | 47.77M | 39.80M | 33.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 61.45K | 0.00 |
| Interest Expense | 21.39M | 54.42M | 48.05M | 41.14M | 30.52M | 29.27M | 14.20M | 0.00 | 0.00 | 0.00 | 0.00 | 13.48K | 0.00 |
| Depreciation & Amortization | 6.52M | 2.16M | 4.41M | 8.89M | 4.58M | 4.60M | 3.83M | 1.69M | 442.80K | 105.68K | 201.32K | 410.60K | 479.50K |
| EBITDA | -61.70M | -53.60M | -212.20M | -303.54M | -278.72M | -331.10M | -398.63M | -226.43M | 57.66M | -10.90M | 5.71M | -14.46M | -16.06M |
| EBITDA Ratio | -21.59% | -14.75% | -67.86% | -120.45% | -155.01% | -252.83% | -1,597.67% | -8,139.07% | 3,310.10% | -672.47% | 233.52% | -801.31% | 0.00% |
| Operating Income | -68.22M | -55.76M | -216.61M | -312.43M | -285.49M | -335.61M | -402.54M | -229.16M | -113.17M | -39.45M | -18.91M | -14.88M | -16.35M |
| Operating Income Ratio | -23.88% | -15.34% | -69.27% | -123.98% | -158.78% | -256.28% | -1,613.31% | -8,237.10% | -6,496.56% | -2,432.85% | -773.25% | -824.06% | 0.00% |
| Total Other Income/Expenses | -106.64M | -35.67M | -43.64M | -32.25M | -23.75M | -24.76M | -10.29M | 2.73M | -170.06M | -28.34M | -24.73M | 0.00 | 1.27M |
| Income Before Tax | -174.86M | -91.43M | -274.88M | -344.68M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -13.83M | -15.09M |
| Income Before Tax Ratio | -61.20% | -25.15% | -87.91% | -136.78% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -766.17% | 0.00% |
| Income Tax Expense | -290.03M | 53.60M | 49.35M | 46.37M | 6.77M | 29.19M | 14.27M | 1.04M | 170.39M | 28.44M | 24.42M | -1.09M | -672.48K |
| Net Income | 115.17M | -145.02M | -324.23M | -391.05M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -12.74M | -15.09M |
| Net Income Ratio | 40.31% | -39.90% | -103.69% | -155.18% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -705.64% | 0.00% |
| EPS | 3.41 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| EPS Diluted | 3.40 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| Weighted Avg Shares Out | 33.82M | 31.86M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
| Weighted Avg Shares Out (Dil) | 33.84M | 31.89M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates
Intercept (ICPT) delivered earnings and revenue surprises of -159.49% and 2.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
U.S. Ocaliva® net sales of $77.6 million; 16.4% growth over the prior year quarter
Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022
Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2022 financial results prior to...
Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients
Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday. The post Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients appeared first on Investor's Business Daily.
Why Is Intercept Pharmaceuticals (ICPT) Stock Down 20% Today?
Today is a big day for Intercept Pharmaceuticals (NASDAQ: ICPT ). The company just announced the clinical-trial results of Intercept's treatment for NASH cirrhosis.
Nike's Down, but These 2 Nasdaq Stocks Fell Even Further Friday
Poor earnings and a business setback were costly for these companies.
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study Company remains on track to resubmit new drug...
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.
Why Is Intercept Pharmaceuticals (ICPT) Stock Up Today?
Source: Postmodern Studio / Shutterstock Intercept Pharmaceuticals (NASDAQ: ICPT ) stock is on the move Wednesday after giving investors an update on how it improved its financials. A press release from the biopharmaceutical company covers several recent transactions.
Source: https://incomestatements.info
Category: Stock Reports